The European Medicines Agency’s advisory committee recommended Foundayo (orforglipron), Eli Lilly and Company’s once-daily oral GLP-1 treatment for obesity and type 2 diabetes. The recommendation is a key step toward a potential final decision by the European Commission.
The decision supports Lilly’s strategy to expand its weight-loss portfolio beyond injectable drugs such as Zepbound. An oral option could improve patient convenience and broaden access in the growing obesity-treatment market.
Analysts and commentators see Foundayo and other investigational drugs as potential drivers of Lilly’s next phase of growth and a way to reduce reliance on current blockbuster injectables.